Background: Activation of muscarinic receptors reduces pain at the spinal level. Results: M 2 and M 4 subtypes mediate muscarinic inhibition of sensory nerve input. M 5 subtype stimulation directly increases sensory input or indirectly inhibits it through metabotropic glutamate receptors. Conclusion: M 2 , M 4 , and M 5 subtypes differentially regulate nociceptive input to the spinal cord. Significance: This study demonstrates how individual muscarinic receptor subtypes control pain transmission.
many G i/o -coupled receptors (21) . Interestingly, stimulation of mAChRs potentiates glutamate release in the majority of spinal dorsal horn neurons in mice (22) , which makes it difficult to explain the analgesic effect of mAChR agonists and acetylcholinesterase inhibitors. Therefore, it is important to determine how each mAChR subtype specifically regulates primary afferent input to second-order dorsal horn neurons in the spinal cord.
In the present study, we took advantage of available mAChR subtype single-and double-KO mice to define the function of individual mAChR subtypes involved in the regulation of primary afferent input to dorsal horn neurons. Our study provides unambiguous evidence that activation of the M 2 and M 4 subtypes directly inhibits primary afferent input to spinal dorsal horn neurons. Our study also reveals a complex role of the M 5 subtype in regulating primary afferent input; activation of the M 5 subtype expressed at primary afferent terminals potentiates primary afferent input, whereas stimulation of the M 5 subtype can also indirectly inhibit primary afferent input through increased glutamate release from spinal interneurons and subsequent activation of group II/III metabotropic glutamate receptors (mGluRs). This new information advances our understanding of how individual mAChR subtypes control nociceptive input and will help in the designing of effective strategies for pain control using mAChR subtype-selective analgesics.
EXPERIMENTAL PROCEDURES
Animals-Wild-type (WT) and mAChR subtype single-and double-KO mice (male, 6 -8 weeks old) were obtained from NIDDK, National Institutes of Health (Bethesda, MD). All experimental protocols and procedures were approved by the Animal Care and Use Committee of the University of Texas M.D. Anderson Cancer Center and conformed to the National Institutes of Health guidelines on the ethical use of animals. The genetic background of the M 2 -KO, M 4 -KO, and M 2 /M 4 double-KO mice was C57/BL6. The M 3 -KO, M 5 -KO, and M 1 /M 3 double-KO mice were maintained on a mixed 129SvEv (50%)/CF1 (50%) background. WT mice with the same mixed genetic background served as controls for mutant mice. The generation of the M 2 -KO, M 3 -KO, M 4 -KO, M 5 -KO, M 1 /M 3 double-KO, and M 2 /M 4 double-KO mice was described previously (14, 16, (23) (24) (25) (26) . Mouse genotyping was carried out using polymerase chain reaction analysis of tail DNA (14, 16, 23, 24) .
Spinal Cord Slice Preparation-The lumbar segment of the spinal cord was rapidly removed through laminectomy after the mice were anesthetized with 2-3% isoflurane. The animals were then euthanized by inhalation of 5% isoflurane. The spinal tissue was immediately placed in ice-cold sucrose artificial cerebrospinal fluid presaturated with 95% O 2 and 5% CO 2 . The sucrose artificial cerebrospinal fluid contained 206 mM sucrose, 2.8 mM KCl, 1.0 mM MgCl 2 , 1.0 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 25.0 mM glucose, and 26.0 mM NaHCO 3 . Transverse spinal cord slices (350 m thick) were cut using a vibratome in the ice-cold sucrose artificial cerebrospinal fluid and preincubated in Krebs' solution oxygenated with 95% O 2 and 5% CO 2 at 34°C for at least 1 h before they were transferred to the recording chamber. The Krebs' solution contained 117.0 mM NaCl, 3.6 mM KCl, 1.2 mM MgCl 2 , 2.5 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 11.0 mM glucose, and 25.0 mM NaHCO 3 . Each slice was placed in a glass-bot-tomed chamber and was continuously perfused with Krebs' solution at 5.0 ml/min at 34°C.
Electrophysiological Recordings-Recordings of excitatory postsynaptic currents (EPSCs) were performed using the whole-cell voltage clamp method, as we described previously (22, 27, 28) . Neurons located in the outer zone of lamina II were identified using infrared and differential interference contrast optics. These neurons were selected for recording because they predominantly receive direct input from nociceptive primary afferents (20, 27, 29) . Recording electrodes with a resistance of 5-10 megaohms were pulled from borosilicate glass capillaries and filled with internal solution containing 135.0 mM potassium gluconate, 5.0 mM KCl, 2.0 mM MgCl 2 , 0.5 mM CaCl 2 , 5.0 mM HEPES, 5.0 mM EGTA, 5.0 mM ATP-Mg, 0.5 mM Na-GTP, 1.0 mM GDP␤S, and 10.0 mM lidocaine N-ethyl bromide, adjusted to pH 7.2-7.4 with 1 M KOH (290 -300 mosM). GDP␤S, a general G protein inhibitor, was added to the internal solution to block the postsynaptic effect mediated by mAChR agonists through G proteins (27, 30) .
EPSCs were elicited by electrical stimulation (0.2 ms, 0.3-0.6 mA, 0.2 Hz) through a bipolar tungsten electrode placed on the dorsal root, which stimulates both A␦and C-fibers (27, 30) . EPSCs were recorded at a holding potential of Ϫ60 mV in the presence of 2 M strychnine (a glycine receptor antagonist) and 10 M bicuculline (a GABA A receptor antagonist). Monosynaptic EPSCs were identified on the basis of their constant latency and the absence of conduction failure of evoked EPSCs in response to a 20-Hz electrical stimulation (27, 31) . Recordings of EPSCs began 6 -7 min after whole-cell access was established and the current reached a steady state. In some neurons, a paired pulse protocol (29) was used to confirm the presynaptic effect of oxotremorine-M. The paired pulse ratio was expressed as the ratio of the amplitude of the second synaptic response to the amplitude of the first synaptic response. The input resistance was monitored, and the recording was abandoned if it changed more than 15%. The signals were processed with an amplifier (MultiClamp700A; Axon Instruments, Union City, CA), filtered at 1-2 kHz, digitized at 10 kHz, and stored in a computer.
Oxotremorine-M and himbacine were obtained from Sigma-Aldrich. (RS)-C-cyclopropyl-4-phosphonophenylglycine (CPPG), (␣R)-␣-cyclopentyl-␣-hydroxy-N-[1-(4-methyl-3-pentenyl)-4-piperidinyl]benzeneacetamide fumarate (J104129), and (2S,1ЈS,2ЈS)-2-(2-carboxycyclopropyl)-2-(9H-xanthen-9-yl) glycine (LY341495) were purchased from Tocris (Ellisville, MO). All of the drugs were dissolved in Krebs' solution immediately before the experiment was started and were perfused using syringe pumps.
Data Analysis-Data are presented as means Ϯ S.E. The amplitude of evoked EPSCs was analyzed using Clampfit (Axon Instruments). The effect of drugs on EPSCs was analyzed over a period of 3 min during drug application. Neurons were considered to be responsive to oxotremorine-M if the amplitude of evoked EPSCs was altered by Ͼ15%. The drug effect on the amplitude of EPSCs was determined by using repeated measures analysis of variance with Dunnett's or Tukey's post hoc test. The difference in the percentage of neurons responsive to oxotremorine-M between WT and mAChR subtype-KO mice was determined using Fisher's exact test. p Ͻ 0.05 was considered to be statistically significant.
RESULTS

Effect of Oxotremorine-M on Primary Afferent Stimulationevoked Glutamatergic EPSCs in WT Mice-
To determine the effect of oxotremorine-M on glutamate release from primary afferents to lamina II neurons, the effect of this agent on identified monosynaptic EPSCs in WT mice was studied. Glutamatergic EPSCs were elicited by electrical stimulation of the dorsal root. Oxotremorine-M (1, 3, 5, and 10 M), a specific mAChR agonist that acts on all five mAChR subtypes, was perfused in a cumulative fashion onto the slice chamber. Each concentration was applied for 3 min. Because the effect of oxotremorine-M on glutamatergic EPSCs was similar among two the WT groups of mice (C57/BL6 and 129SvEv/CF1 genetic backgrounds) (22) , data obtained from the two WT control groups were pooled. Oxotremorine-M at 1-10 M produced a concentration-dependent reduction in the peak amplitude of monosynaptic EPSCs in 16 neurons examined (Fig. 1, A and B) . Also, oxotremorine-M concentration-dependently reduced the amplitude of polysynaptic EPSCs (reflecting glutamate release from both primary afferent terminals and interneurons) in another 14 neurons tested. The inhibitory effect of oxotremorine-M was significantly greater in polysynaptic EPSCs than in monosynaptic EPSCs in lamina II neurons ( Fig. 1, A and B) .
In lamina II neurons recorded from WT mice, oxotremorine-M at 3 M significantly inhibited the amplitude of monosynaptic EPSCs in 52 of 78 (66.7%) neurons ( Fig. 1D) . Similarly, oxotremorine-M significantly reduced the amplitude of polysynaptic EPSCs in 31 of 45 (68.8%) neurons. Bath application of 3 M oxotremorine-M either had no effect or significantly increased the amplitude of monosynaptic and polysynaptic EPSCs in a small population of lamina II neurons ( Fig. 1, C and D) .
To determine the role of M 2 and M 4 subtypes in the inhibitory effect of oxotremorine-M on synaptic glutamate release from primary afferents in WT mice, we used himbacine, a selective antagonist for M 2 and M 4 subtypes (28, (32) (33) (34) . After the initial effect of 3 M oxotremorine-M on monosynaptic EPSCs was tested, 2 M himbacine was bath-perfused for 3 min before reapplication of oxotremorine-M. The effective concentration of himbacine has been determined previously (28, 35) . In 12 of 19 neurons in which initial application of oxotremorine-M significantly reduced the amplitude of monosynaptic EPSCs, himbacine abolished the inhibitory effect of oxotremorine-M on the amplitude of EPSCs ( Fig. 2A ). In the remaining seven neurons, himbacine only partially blocked the inhibitory effect of oxotremorine-M. To determine whether group II/III mGluRs are involved in the inhibitory effect of oxotremorine-M on glutamate release from primary afferents, we used LY341495 and CPPG, which are group II and group III mGluR antagonists, respectively (36, 37) . The remaining inhibitory effect of oxotremorine-M on monosynaptic EPSCs was completely blocked by subsequent treatment with 100 nM LY341495 plus 200 M CPPG in these seven neurons ( Fig. 2A ).
In 15 lamina II neurons recorded from WT mice, the inhibitory effect of 3 M oxotremorine-M on the amplitude of polysynaptic EPSCs was completely blocked by 2 M himbacine in nine neurons (Fig. 2B ). In the remaining six neurons, himbacine did not fully block the inhibitory effect of oxotremorine-M on polysynaptic EPSCs. Subsequent application of 100 nM LY341495 plus 200 M CPPG abolished the remaining inhibitory effect of oxotremorine-M on polysynaptic EPSCs in these six neurons (Fig. 2B) .
In an additional nine neurons, bath application of oxotremorine-M significantly increased the paired pulse ratio of monosynaptic EPSCs evoked from the dorsal root ( Fig. 2C ), suggesting a presynaptic effect of oxotremorine-M. We also determined the role of group II/III mGluRs in muscarinic inhibition of monosynaptic EPSCs in the absence of himbacine. Treatment with LY341495 and CPPG abolished the inhibitory effect of oxotremorine-M on monosynaptic EPSCs in 8 of 20 neurons and partially inhibited the oxotremorine-M effect in the remaining 12 neurons (Fig. 2D) .
Effect of Oxotremorine-M on Primary Afferent Stimulationevoked EPSCs in M 2 /M 4 Double-KO Mice-To delineate the role of both M 2 and M 4 subtypes in the action of oxotremorine-M on glutamate release from primary afferents, we tested not alter the inhibitory effect of oxotremorine-M on evoked EPSCs.
In addition, we determined whether the M 3 subtype is involved in the potentiating effect of oxotremorine-M on evoked EPSCs in the spinal cord slices of M 2 /M 4 double-KO mice. We used J104129, an M 3 subtype-preferring antagonist (22, 38) . Bath application of 50 nM J104129 did not significantly alter the potentiating effect of oxotremorine-M on the peak amplitude of monosynaptic EPSCs or polysynaptic EPSCs in all lamina II neurons tested (Fig. 3D) . These results indicate that the M 2 /M 4 subtypes contribute to mAChR activation-induced reduction in glutamatergic input from primary afferents and that group II/III mGluRs mediate the inhibition of primary afferent input by mAChR activation in the spinal dorsal horn.
Effect Fig. 5A ). In 12 of 46 (26.1%) neurons, oxotremorine-M significantly increased the amplitude of monosynaptic EPSCs (Fig. 5A ). Compared with WT mice, oxotremorine-M inhibited monosynaptic EPSCs in significantly fewer neurons and potentiated monosynaptic EPSCs in significantly more neurons in M 4 -KO mice.
In 10 of 17 lamina II neurons recorded from M 4 -KO mice, himbacine completely blocked the inhibitory effect of 3 M oxotremorine-M on the amplitude of monosynaptic EPSCs (Fig. 5B) . In another seven neurons, himbacine did not fully block the inhibitory effect of oxotremorine-M on monosynaptic EPSCs, but this remaining inhibitory effect was abolished by subsequent treatment with LY341495 and CPPG (Fig. 5C ). The above data indicate that M 2 and M 4 subtypes as well as group II/III mGluRs are involved in inhibition of glutamatergic input from primary afferents to dorsal horn neurons by mAChR activation. MAY (Fig. 6A) .
Effect of Oxotremorine-M on Primary Afferent Stimulationevoked EPSCs in M 1 /M 3 Double-KO
Control of Nociceptive Input by Muscarinic Receptors
In 12 of 19 lamina II neurons from M 1 /M 3 double-KO mice in which initial oxotremorine-M inhibited the amplitude of monosynaptic EPSCs, bath application of 2 M himbacine abolished the effect of oxotremorine (Fig. 6, B and C) . In the rest of the seven neurons, himbacine did not fully block the inhibitory effect of oxotremorine-M on the amplitude of monosynaptic EPSCs. This remaining inhibitory effect was completely blocked by subsequent application of 100 nM LY341495 and 200 M CPPG (Fig. 6C ).
In 12 of 21 lamina II neurons with polysynaptic EPSCs recorded from M 1 /M 3 double-KO mice, himbacine abolished the inhibitory effect of oxotremorine-M. In the remaining nine neurons, himbacine only partially reduced the inhibitory effect of oxotremorine-M. The residual effect of oxotremorine-M on polysynaptic EPSCs was completely blocked by further treatment with LY341495 and CPPG in these nine neurons (Fig. 6D) .
Effect of Oxotremorine-M on Primary Afferent Stimulationevoked EPSCs in M 3 -KO Mice-
We also explored whether the M 3 subtype could be involved in the control of primary afferent input by mAChRs. In a total of 32 lamina II neurons from M 3 -KO mice, 3 M oxotremorine-M significantly decreased the amplitude of monosynaptic EPSCs in 21 (65.6%) neurons. In another 4 of 32 (12.5%) neurons, oxotremorine-M significantly increased the amplitude of monosynaptic EPSCs (Fig. 7A) .
In 12 of 20 lamina II neurons recorded from M 3 -KO mice, himbacine abolished oxotremorine-M-induced inhibition of the amplitude of monosynaptic EPSCs (Fig. 7B ). In the remaining eight neurons, oxotremorine-M still significantly attenuated the amplitude of monosynaptic EPSCs in the presence 2 M himbacine. This remaining inhibitory effect was abolished by subsequent application of 100 nM LY341495 and 200 M CPPG (Fig. 7C ). Because the inhibitory and potentiating effects of oxotremorine-M on monosynaptic EPSCs in M 1 /M 3 double-KO mice and M 3 -KO mice were similar to those in WT mice, we conclude that M 1 and M 3 subtypes do not contribute significantly to the regulation of primary afferent input by mAChRs.
Effect of Oxotremorine-M on Primary Afferent Stimulationevoked EPSCs in M 5 -KO Mice-In addition, we determined whether the M 5 subtype contributes to the regulation of primary afferent input by mAChRs using M 5 -KO mice. In 23 of 37 (62.2%) lamina II neurons from M 5 -KO mice, 3 M oxotremorine-M significantly inhibited the peak amplitude of monosynaptic EPSCs. Oxotremorine-M had no significant effect on the amplitude of monosynaptic EPSCs in the rest of 14 (37.8%) neurons (Fig. 8A) . The proportion of neurons with different responses to oxotremorine-M (i.e. by decreasing or increasing the amplitude of monosynaptic EPSCs) in WT and various mAChR subtype-KO mice is summarized in Fig. 9 . For polysynaptic EPSCs evoked from the dorsal root, 3 M oxotremorine-M significantly reduced the amplitude of EPSCs in 22 of 36 (61.1%) neurons but had no effect on polysynaptic EPSCs in the remaining 14 (39.9%) neurons from M 5 -KO mice (Fig. 8A) .
Furthermore, in lamina II neurons in which oxotremorine-M initially reduced the amplitude of monosynaptic and polysynaptic EPSCs recorded from M 5 -KO mice, himbacine alone completely blocked the inhibitory effect of oxotremorine-M on monosynaptic and polysynaptic EPSCs in all neurons tested (Fig. 8, B and C) . These data indicate that direct activation of the M 5 subtype located on primary afferent terminals potentiates primary afferent input. Also, the M 5 subtype is indirectly involved in the inhibition of primary afferent input by group II/III mGluRs following mAChR stimulation in the spinal cord.
DISCUSSION
The major objective of this study was to combine genetic and electrophysiological approaches to define the functional role of individual mAChR subtypes in the regulation of primary afferent input to spinal dorsal horn neurons. Because there are no highly selective mAChR subtype agonists and antagonists, it is difficult to rely on pharmacological agents alone to delineate the specific role of individual mAChR subtypes in the regulation of nociceptive transmission at the spinal level. The use of spinal cord slice preparation is appropriate for this study, because it preserves the intrinsic connection between primary afferent terminals and second-order neurons, where native mAChR subtypes are expressed. We reported previously that the mAChR agonist oxotremorine-M increased the frequency of spontaneous EPSCs in two-thirds of lamina II neurons in WT mice (22) . However, increased glutamatergic transmission in the spinal cord by mAChR activation is inconsistent with the potent inhibitory effects of mAChR agonists on nociception and the excitability of spinal dorsal horn neurons in vivo (5, 14, 39) . Also, recordings of spontaneous EPSCs alone cannot identify the sources of glutamate release, especially glutamatergic input from primary afferent nerves. Therefore, in this study, we specifically determined how each mAChR subtype regulates primary afferent input by recording monosynaptic EPSCs evoked from the dorsal root. We found that oxotremorine-M significantly decreased the amplitude of monosynaptic and polysynaptic EPSCs in about two-thirds of lamina II neurons in WT mice. Furthermore, blocking M 2 and M 4 subtypes with himbacine (32, 33) either completely or partially blocked the inhibitory effect of oxotremorine-M in all laminar II neurons examined in WT mice. Interestingly, oxotremorine-M inhibited polysynaptic EPSCs more than monosynaptic EPSCs in dorsal horn neurons in WT mice. This result is probably due to the presence of additional M 2 /M 4 subtypes and group II/II mGluRs on spinal cord interneurons involved in the polysynaptic transmission. These data suggest that activation of presynaptic M 2 and M 4 subtypes inhibits excitatory glutamatergic input from primary afferents in the majority of dorsal horn neurons.
Our study provides unambiguous evidence showing that both M 2 and M 4 subtypes are expressed at primary afferent terminals to inhibit their input to dorsal horn neurons. In support of this conclusion, we found that the inhibitory effect of oxotremorine-M on monosynaptic and polysynaptic EPSCs evoked by dorsal root stimulation was significantly reduced and occurred in significantly fewer dorsal horn neurons in M 2 /M 4 double-KO mice than in WT mice. Because himbacine still significantly attenuated the inhibitory effect of oxotremorine-M on monosynaptic EPSCs in M 2 single-KO and M 4 single-KO mice, these data indicate that both M 2 and M 4 subtypes contribute to muscarinic inhibition of primary afferent input. In the spinal cord, the M 2 subtype represents ϳ90% of mAChRs, which are mainly distributed in the superficial dorsal horn (13, 14, 40) . Stimulation of the M 2 and M 4 subtypes can inhibit the activity of voltage-gated calcium channels in primary sensory neurons (9) , which can explain their inhibitory effect on monosynaptic and polysynaptic EPSCs evoked from the dorsal root. Although the spinal M 4 subtype is expressed at low levels (14, 15) , its expression level is significantly increased in primary sensory neurons in painful diabetic neuropathy (9) . Thus, the M 4 subtype remains an attractive therapeutic target for neuropathic pain control. Our electrophysiological results are consistent with animal behavioral data regarding the critical role of the M 2 and M 4 subtypes involved in muscarinic analgesia at the spinal level (5, 14) .
Another salient finding of our study is that the M 5 subtype plays a complex role in regulating primary afferent input. We found that in WT mice, oxotremorine-M significantly increased the amplitude of monosynaptic and polysynaptic EPSCs in a small population (10 -13%) of dorsal horn neurons. This potentiating effect became more pronounced in many dorsal horn neurons recorded from M 2 /M 4 double-KO mice. We found that blocking the M 3 subtype did not significantly alter the stimulating effect of oxotremorine-M on evoked EPSCs in M 2 /M 4 double-KO mice. Furthermore, the stimulating effect of oxotremorine-M on monosynaptic and polysynaptic EPSCs was not altered in M 3 -KO and M 1 /M 3 double-KO mice. Thus, the M 1 and M 3 subtypes are not significantly involved in the muscarinic control of primary afferent input. Strikingly, the potentiating effect of oxotremorine-M on evoked EPSCs was completely absent in M 5 -KO mice. These findings indicate that the M 5 subtype is expressed at the primary afferent terminals and that its stimulation can increase primary sensory input in a subpopulation of dorsal horn neurons.
We previously showed that the M 5 subtype is mainly responsible for the increased frequency of spontaneous glutamatergic EPSCs and indirect activation of group II/III mGluRs in the spinal cord induced by oxotremorine-M (22) . Group II/III mGluRs are G i/o -protein-coupled receptors, which can inhibit voltage-gated calcium channels (41, 42) and attenuate glutamatergic transmission in the spinal dorsal horn (43, 44) . When spinal glutamate release is potentiated by oxotremorine-M, glutamate can spill over to activate group II/III mGluRs present at adjacent primary afferent terminals, where they provide negative feedback regulation of glutamate release to dorsal horn neurons (37, 43) . We found in this study that the inhibitory effect of oxotremorine-M on monosynaptic and polysynaptic EPSCs was still present in M 2 /M 4 double-KO mice and in the presence of himbacine in WT mice. Blocking group II/III mGluRs with LY341495 and CPPG abolished the remaining inhibitory effect of oxotremorine-M on the amplitude of monosynaptic and polysynaptic EPSCs in WT mice and in M 2 /M 4 double-KO mice. Importantly, the inhibitory effect of oxotremorine-M on monosynaptic and polysynaptic EPSCs was completely blocked by himbacine alone in all dorsal horn neurons from M 5 -KO mice. Therefore, in addition to its potentiating effect on glutamate release from primary afferents, the M 5 subtype is critically involved in subsequent activation of group II/III mGluRs to restrain excessive primary afferent input to the spinal cord.
Our study uncovers a complex and reciprocal interaction between the M 2 /M 4 subtypes, the M 5 subtype, and group II/III mGluRs at the same or different primary afferent terminals ( Fig. 10 ). On the one hand, the M 5 subtype is present on a small subset of primary afferent terminals, and its activation can cause increased glutamate release. This potentiating effect of the M 5 subtype was especially evident in the absence of M 2 and M 4 subtypes, because oxotremorine-M increased monosynaptic and polysynaptic EPSCs in significantly more dorsal horn neurons in M 2 -KO, M 4 -KO, and M 2 /M 4 double-KO mice than in WT mice. On the other hand, stimulation of the M 5 subtype on glutamatergic interneurons potentiates glutamate release, leading to inhibition of primary afferent input via group II/III mGluRs. The latter action may consequently reduce nociceptive transmission, and it is possible that blocking group II/III mGluRs could attenuate the analgesic effect of spinally administered mAChR agonists. The fact that the M 5 subtype is involved in both potentiation of primary afferent input and attenuation of primary afferent input (indirectly via group II/III mGluRs) could explain why the inhibitory effect of oxotremorine-M on monosynaptic and polysynaptic EPSCs was not significantly potentiated or reduced in M 5 -KO mice. It will be interesting to determine how the muscarinic analgesic effect is altered in M 5 -KO mice.
In summary, our study using mAChR subtype-KO mice revealed that M 2 , M 4 , and M 5 subtypes are present at primary afferent terminals and differentially regulate nociceptive transmission in the spinal cord. Our study provides unequivocal evidence that mAChR agonist-induced inhibition of glutamatergic input from primary afferents is largely mediated by M 2 and M 4 subtypes. Stimulation of the M 5 subtype can directly increase primary afferent input and indirectly lead to activation of group II/III mGluRs, which participate in the negative feedback control of glutamate release from primary afferents. This new information is critical to our understanding of how individual mAChR subtypes regulate nociceptive input to the spinal dorsal horn. Our findings are also important for the development of novel subtype-specific mAChR analgesics with improved efficacy and reduced side effects. FIGURE 10 . Schematic drawing showing the distribution of the three mAChR subtypes on primary afferent terminals and glutamatergic interneurons in the mouse spinal dorsal horn. In this diagram, the primary afferent nerve terminal contacts the recorded postsynaptic neuron either directly (monosynaptic) or indirectly through the glutamatergic interneuron (polysynaptic). The functional interaction between the M 2 , M 4 , and M 5 subtypes and group II/III mGluRs in the control of glutamate release from primary afferent nerves is described in detail under "Discussion."
